Studies observed that RA patients who had high serum pretreatment ratio of type I IFNβ/α (> 1.3) or undetectable type I IFN were likely to have EULAR nonresponse to TNF inhibitors (including certolizumab pegol) (174, 175). This evidence concerns the gene TNF and rheumatoid arthritis.